Pathogenic bone loss in rheumatoid arthritis: Mechanisms and therapeutic approaches

International Journal of Clinical Rheumatology

Volumn 4, Issue 5, 2009, Pages 561-582

  Cantley, Melissa D ^a   Smith, Malcolm D ^b   Haynes, David R ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b REPATRIATION GENERAL HOSPITAL   (Australia)

Author keywords

Anti inflammatory treatments; Antiresorptive treatments; B ligand; NFATc1; Nuclear factor of activated T cells; Osteoclasts receptor activator of nuclear factor; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; BISPHOSPHONIC ACID DERIVATIVE; CATHEPSIN K INHIBITOR; COLONY STIMULATING FACTOR 1; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ESTROGEN; ETANERCEPT; FLOBUFEN; GLUCOCORTICOID; GOLD DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOPROTEGERIN; PENICILLAMINE; PHOSPHOTRANSFERASE INHIBITOR; PREDNISONE; RALOXIFENE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; VITAMIN D;

ALBERS SCHOENBERG DISEASE; B LYMPHOCYTE; BONE DISEASE; BONE EROSION; BONE METABOLISM; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; FIBROBLAST; FRAGILITY FRACTURE; HORMONE SUBSTITUTION; HUMAN; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS;

EID: 71249093770     PISSN: 17584272     EISSN: None     Source Type: Journal    
DOI: 10.2217/ijr.09.42     Document Type: Review

References (193)

1. Findlay DM, Haynes DR: Mechanisms of bone loss in rheumatoid arthritis. Mod. Rheumatol. 15, 232-240 (2005).
2. Jacobson JA, Girish G, Jiang Y, Resnick D: Radiographic evaluation of arthritis: inflammatory conditions. Radiology 248, 378-389 (2008).
3. Langs G, Peloschek P, Bischof H, Kainberger F: Automatic quantification of joint space narrowing and erosions in rheumatoid arthritis. IEEE Trans. Med. Imaging 28, 151-164 (2009).
4. Walsh NC, Crotti TN, Goldring SR, Gravallese EM: Rheumatic diseases: the effects of inflammation on bone. Immunol. Rev. 208, 228-251 (2005).
5. Romas E, Gillespie MT: Inflammation-induced bone loss: can it be prevented? Rheum. Dis. Clin. North Am. 32, 759-773 (2006).
6. Schett G: Erosive arthritis. Arthritis Res. Ther. 9, S2 (2007).
7. Schett G, Stach C, Zwerina J, Voll R, Manger B: How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum. 58, 2936-2948 (2008).
8. Goldring SR: Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology (Oxford) 42, II11-II16 (2003).
9. Goldring MB, Suen LF, Yamin R, Lai WF: Regulation of collagen gene expression by prostaglandins and interleukin-1β in cultured chondrocytes and fibroblasts. Am. J. Ther. 3, 9-16 (1996).
10. Stephenson ML, Goldring MB, Birkhead JR, Krane SM, Rahmsdorf HJ, Angel P: Stimulation of procollagenase synthesis parallels increases in cellular procollagenase mRNA in human articular chondrocytes exposed to recombinant interleukin 1 β or phorbol ester. Biochem. Biophys. Res. Commun. 144, 583-590 (1987).
11. Deodhar AA, Woolf AD: Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br. J. Rheumatol. 35, 309-322 (1996).
12. Guler-Yuksel M, Allaart CF, Goekoop-Ruiterman YP et al.: Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann. Rheum. Dis. 68, 330-336 (2009).
13. Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP et al.: Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann. Rheum. Dis. 67, 823-828 (2008).
14. Guler-Yuksel M, Allaart CF, Goekoop-Ruiterman YP et al.: Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann. Rheum. Dis. 68, 330-336 (2009).
15. Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP et al.: Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann. Rheum. Dis. 67, 823-828 (2008).
16. Goldring SR: Periarticular bone changes in rheumatoid arthritis: pathophysiological implications and clinical utility. Ann. Rheum. Dis. 68, 297-299 (2009).
17. van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C: Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 54, 3104-3112 (2006).
18. Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentiation and activation. Nature 423, 337-342 (2003).
19. Lerner UH: Osteoclast formation and resorption. Matrix Biol. 19, 107-120 (2000).
20. Rubin J, Greenfield E: Osteoclast: origin and differentiation. In: Topics in Bone Biology - Bone Resorption. Bronner F, Farach-Carson MC, Rubin R (Eds). Springer-Verlag, London, UK, 2 (2005).
21. Pettit AR, Ji H, von Stechow D et al.: TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am. J. Pathol. 159, 1689-1699 (2001).
22. Redlich K, Hayer S, Ricci R et al.: Osteoclasts are essential for TNF-α-mediated joint destruction. J. Clin. Invest. 110, 1419-1427 (2002).
23. Fujikawa Y, Sabokbar A, Neale S, Athanasou NA: Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis. Ann. Rheum. Dis. 55, 816-822 (1996).
24. Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM: Osteoprotegerin and receptor activator of nuclear factor kB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford) 40, 623-630 (2001).
25. Suzuki Y, Tsutsumi Y, Nakagawa M et al.: Osteoclast-like cells in an in vitro model of bone destruction by rheumatoid synovium. Rheumatology (Oxford) 40, 673-682 (2001).
26. Toritsuka Y, Nakamura N, Lee SB et al.: Osteoclastogenesis in iliac bone marrow of patients with rheumatoid arthritis. J. Rheumatol. 24, 1690-1696 (1997).
27. Kuratani T, Nagata K, Kukita T, Hotokebuchi T, Nakasima A, Iijima T: Induction of abundant osteoclast-like multinucleated giant cells in adjuvant arthritic rats with accompanying disordered high bone turnover. Histol. Histopathol. 13, 751-759 (1998).
28. Suzuki Y, Nishikaku F, Nakatuka M, Koga Y: Osteoclast-like cells in murine collagen induced arthritis. J. Rheumatol. 25, 1154-1160 (1998).
29. Takayanagi H, Sato K, Takaoka A, Taniguchi T: Interplay between interferon and other cytokine systems in bone metabolism. Immunol. Rev. 208, 181-193 (2005).
30. Chambers TJ: Regulation of the differentiation and function of osteoclasts. J. Pathol. 192, 4-13 (2000).
31. Kodama H, Nose M, Niida S, Yamasaki A: Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J. Exp. Med. 173, 1291-1294 (1991).
32. Sarma U, Flanagan AM: Macrophage colony-stimulating factor induces substantial osteoclast generation and bone resorption in human bone marrow cultures. Blood 88, 2531-2540 (1996).
33. Teitelbaum SL: Osteoclasts: what do they do and how do they do it? Am. J. Pathol. 170, 427-435 (2007).
34. Lacey DL, Timms E, Tan HL et al.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176 (1998).
35. Matsuzaki K, Udagawa N, Takahashi N et al.: Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem. Biophys. Res. Commun. 246, 199-204 (1998).
36. Kobayashi K, Takahashi N, Jimi E et al.: Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191, 275-286 (2000).
37. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL: TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106, 1481-1488 (2000).
38. Hofbauer LC, Heufelder AE: Role of receptor activator of nuclear factor-kB ligand and osteoprotegerin in bone cell biology. J. Mol. Med. 79, 243-253 (2001).
39. Caetano-Lopes J, Canhão H, Fonseca JE: Osteoimmunology - the hidden immune regulation of bone. Autoimmun. Rev. 8, 250-255 (2009).
40. Crotti T, Smith MD, Hirsch R et al.: Receptor activator NF kB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J. Periodont. Res. 38, 380-387 (2003).
41. Crotti TN, Ahern MJ, Lange K et al.: Variability of RANKL and osteoprotegerin staining in synovial tissue from patients with active rheumatoid arthritis: quantification using color video image analysis. J. Rheumatol. 30, 2319-2324 (2003).
42. Crotti TN, Smith MD, Weedon H et al.: Receptor activator NF-kB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann. Rheum. Dis. 61, 1047-1054 (2002).
43. Pettit AR, Walsh NC, Manning C, Goldring SR, Gravallese EM: RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology (Oxford) 45, 1068-1076 (2006).
44. Haynes DR: Emerging and future therapies for the treatment of bone loss associated with chronic inflammation. Inflammopharmacology 14, 193-197 (2006).
45. Horwood NJ, Kartsogiannis V, Quinn JM, Romas E, Martin TJ, Gillespie MT: Activated T lymphocytes support osteoclast formation in vitro. Biochem. Biophys. Res. Commun. 265, 144-150 (1999).
46. Kong YY, Feige U, Sarosi I et al.: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402, 304-309 (1999).
47. Holding CA, Findlay DM, Stamenkov R et al.: The correlation of RANK, RANKL and TNFα expression with bone loss volume and polyethylene wear debris around hip implants. Biomaterials 27, 5212-5219 (2006).
48. Bucay N, Sarosi I, Dunstan CR et al.: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12, 1260-1268 (1998).
49. Mizuno A, Kanno T, Hoshi M et al.: Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. J. Bone Miner. Metab. 20, 337-344 (2002).
50. Redlich K, Hayer S, Maier A et al.: Tumor necrosis factor α-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum. 46, 785-792 (2002).
51. Haynes DR, Barg E, Crotti TN et al.: Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology (Oxford) 42, 123-134 (2003).
52. Takayanagi H: Mechanistic insight into osteoclast differentiation in osteoimmunology. J. Mol. Med. 83, 170-179 (2005).
53. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D: The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 15, 457-475 (2004).
54. Naito A, Azuma S, Tanaka S et al.: Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 4, 353-362 (1999).
55. Tak PP, Gerlag DM, Aupperle KR et al.: Inhibitor of nuclear factor kB kinase β is a key regulator of synovial inflammation. Arthritis Rheum. 44, 1897-1907 (2001).
56. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R: Osteopetrosis in mice lacking NF-kB1 and NF-kB2. Nat. Med. 3, 1285-1289 (1997).
57. Soysa NS, Alles N: NF-kB functions in osteoclasts. Biochem. Biophys. Res. Commun. 378, 1-5 (2009).
58. Ruocco MG, Karin M: IKKβ as a target for treatment of inflammation induced bone loss. Ann. Rheum. Dis. 64, IV81-IV85 (2005).
59. Asagiri M, Takayanagi H: The molecular understanding of osteoclast differentiation. Bone 40, 251-264 (2007).
60. Takayanagi H: Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 7, 292-304 (2007).
61. Johnson RS, Spiegelman BM, Papaioannou V: Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 71, 577-586 (1992).
62. Grigoriadis AE, Wang ZQ, Cecchini MG et al.: c-fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266, 443-448 (1994).
63. Ikeda F, Nishimura R, Matsubara T et al.: Critical roles of c-jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J. Clin. Invest. 114, 475-484 (2004).
64. Asagiri M, Takayanagi H: The molecular understanding of osteoclast differentiation. Bone 40, 251-264 (2007).
65. Matsumoto M, Kogawa M, Wada S et al.: Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J. Biol. Chem. 279, 45969-45979 (2004).
66. Matsuo K, Irie N: Osteoclast-osteoblast communication. Arch. Biochem. Biophys. 473, 201-209 (2008).
67. Sharma SM, Bronisz A, Hu R et al.: MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation. J. Biol. Chem. 282, 15921-15929 (2007).
68. Takayanagi H, Kim S, Koga T et al.: Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3, 889-901 (2002).
69. Takayanagi H, Kim S, Koga T et al.: Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3, 889-901 (2002).
70. Hegen M, Keith JC Jr, Collins M, Nickerson-Nutter CL: Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann. Rheum. Dis. 67, 1505-1515 (2008).
71. Walz DT, DiMartino MJ, Misher A: Adjuvant-induced arthritis in rats. II. Drug effects on physiologic, biochemical and immunologic parameters. J. Pharmacol. Exp. Ther. 178, 223-231 (1971).
72. Sakuma S, Nishigaki F, Magari K et al.: FK506 is superior to methotrexate in therapeutic effects on advanced stage of rat adjuvant-induced arthritis. Inflamm. Res. 50, 509-514 (2001).
73. Morgan SL, Chen DT, Carlee J, Baggott JE: Effect of methotrexate therapy on bone mineral density and body composition in rat adjuvant arthritis. J. Rheumatol. 31, 1693-1697 (2004).
74. Suzuki Y, Nakagawa M, Masuda C et al.: Short-term low dose methotrexate ameliorates abnormal bone metabolism and bone loss in adjuvant induced arthritis. J. Rheumatol. 24, 1890-1895 (1997).
75. Magari K, Miyata S, Nishigaki F, Ohkubo Y, Mutoh S, Goto T: Differential effects of FK506 and methotrexate on inflammatory cytokine levels in rat adjuvant-induced arthritis. J. Rheumatol. 30, 2193-2200 (2003).
76. Haynes DR, Hutchens MJ, Whitehouse MW, Vernon-Roberts B: A comparison of the disease-modifying and cytokine-regulating activities of tenidap, piroxicam and cyclosporin-A using the adjuvant-induced model of arthritis in rats. Inflammopharmacology 6, 193-202 (1998).
77. Haynes DR, Gadd SJ, Whitehouse MW, Mayrhofer G, Vernon-Roberts B: Complete prevention of the clinical expression of adjuvant-induced arthritis in rats by cyclosporin-A and lobenzarit: the regulation of lymph node cell populations and cytokine production. Inflamm. Res. 45, 159-165 (1996).
78. Ghia M, Mattioli F, Novelli F, Minganti V: Inhibitory properties of triethylphosphine goldlupinylsulfide in adjuvant-induced arthritis in rats. Farmaco 50, 601-604 (1995).
79. Feige U, Hu YL, Gasser J, Campagnuolo G, Munyakazi L, Bolon B: Anti-interleukin-1 and anti-tumor necrosis factor-α synergistically in-hibit adjuvant arthritis in Lewis rats. Cell. Mol. Life Sci. 57, 1457-1470 (2000).
80. Bendele AM, Chlipala ES, Scherrer J et al.: Combination benefit of treatment with the cytokine in-hibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum. 43, 2648-2659 (2000).
81. Bendele AM, McComb J, Gould T et al.: Combination benefit of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) and dexamethasone or indomethacin in adjuvant arthritic rats. Inflamm. Res. 48, 453-460 (1999).
82. Khachigian LM: Collagen antibody-induced arthritis. Nat. Protoc. 1, 2512-2516 (2006).
83. Nasu Y, Nishida K, Miyazawa S et al.: Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthr. Cartil. 16, 723-732 (2008).
84. Oestergaard S, Rasmussen KE, Doyle N et al.: Evaluation of cartilage and bone degradation in a murine collagen antibody-induced arthritis model. Scand. J. Immunol. 67, 304-312 (2008).
85. Mitamura M, Nakano N, Yonekawa T et al.: T cells are involved in the development of arthritis induced by anti-type II collagen antibody. Int. Immunopharmacol. 7, 1360-1368 (2007).
86. Kannan K, Ortmann RA, Kimpel D: Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology 12, 167-181 (2005).
87. Li P, Schwarz EM: The TNF-α transgenic mouse model of inflammatory arthritis. Springer Semin. Immunopathol. 25, 19-33 (2003).
88. Ahlqvist E, Hultqvist M, Holmdahl R: The value of animal models in predicting genetic susceptibility to complex diseases such as rheumatoid arthritis. Arthritis Res. Ther. 11, 226 (2009).
89. Noguchi M, Kimoto A, Sasamata M, Miyata K: Micro-CT imaging analysis for the effect of celecoxib, a cyclooxygenase-2 inhibitor, on inflammatory bone destruction in adjuvant arthritis rats. J. Bone Miner. Metab. 26, 461-468 (2008).
90. Barck KH, Lee WP, Diehl LJ et al.: Quantification of cortical bone loss and repair for therapeutic evaluation in collagen-induced arthritis, by micro-computed tomography and automated image analysis. Arthritis Rheum. 50, 3377-3386 (2004).
91. Schopf L, Savinainen A, Anderson K et al.: IKKβ inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis. Arthritis Rheum. 54, 3163-3173 (2006).
92. Cantley MD, Bartold PM, Marino V et al.: The use of live-animal micro-computed tomography to determine the effect of a novel phospholipase A2 inhibitor on alveolar bone loss in an in vivo mouse model of periodontitis. J. Periodont. Res. 44, 317-322 (2009).
93. O'Dell JR: Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum. 46, 283-285 (2002).
94. Doan T, Massarotti E: Rheumatoid arthritis: an overview of new and emerging therapies. J. Clin. Pharmacol. 45, 751-762 (2005).
95. Fujita D, Yamashita N, Iita S, Amano H, Yamada S, Sakamoto K: Prostaglandin E2 induced the differentiation of osteoclasts in mouse osteoblast-depleted bone marrow cells. Prostaglandins Leukot. Essent. Fatty Acids 68, 351-358 (2003).
96. Inada M, Matsumoto C, Uematsu S, Akira S, Miyaura C: Membrane-bound prostaglandin E synthase-1-mediated prostaglandin E2 production by osteoblast plays a critical role in lipopolysaccharide-induced bone loss associated with inflammation. J. Immunol. 177, 1879-1885 (2006).
97. Take I, Kobayashi Y, Yamamoto Y et al.: Prostaglandin E2 strongly inhibits human osteoclast formation. Endocrinology 146, 5204-5214 (2005).
98. Li M, Ke HZ, Qi H et al.: A novel, non-prostanoid EP2 receptor-selective prostaglandin E2 agonist stimulates local bone formation and enhances fracture healing. J. Bone Miner. Res. 18, 2033-2042 (2003).
99. Paralkar VM, Borovecki F, Ke HZ et al.: An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc. Natl Acad. Sci. USA 100, 6736-6740 (2003).
100. Idris AI, Ralston SH, van't Hof RJ: The nitrosylated flurbiprofen derivative HCT1026 inhibits cytokine-induced signalling through a novel mechanism of action. Eur. J. Pharmacol. 602, 215-222 (2009).
101. De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, van Staa TP: Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 56, 208-214 (2007).
102. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C: Use of oral corticosteroids and risk of fractures. June, 2000. J. Bone Miner. Res. 20, 1487-1494 (2005) (Discussion 1486).
103. Bansback NJ, Regier DA, Ara R et al.: An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-α antagonists. Drugs 65, 473-496 (2005).
104. Cronstein BN: Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol. Rev. 57, 163-172 (2005).
105. Emery P, Breedveld FC, Hall S et al.: Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372, 375-382 (2008).
106. Klareskog L, van der Heijde D, de Jager JP et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363, 675-681 (2004).
107. Keystone EC, Kavanaugh AF, Sharp JT et al.: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 50, 1400-1411 (2004).
108. Cohen SB, Moreland LW, Cush JJ et al.: A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann. Rheum. Dis. 63, 1062-1068 (2004).
109. Kremer J, Genovese M, Cannon GW et al.: Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. J. Rheumatol. 31, 1521-1531 (2004).
110. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al.: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a Phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54, 1390-1400 (2006).
111. Klinkhoff A: Biological agents for rheumatoid arthritis: targeting both physical function and structural damage. Drugs 64, 1267-1283 (2004).
112. Herman S, Kronke G, Schett G: Molecular mechanisms of inflammatory bone damage: emerging targets for therapy. Trends Mol. Med. 14, 245-253 (2008).
113. Hoff M, Kvien TK, Kalvesten J, Elden A, Haugeberg G: Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: Explorative analyses from the PREMIER study. Ann. Rheum. Dis. 68(7), 1171-1176 (2008).
114. Haugeberg G: Focal and generalized bone loss in rheumatoid arthritis: separate or similar concepts? Nat. Clin. Pract. Rheumatol. 4, 402-403 (2008).
115. Sambrook P: Tumour necrosis factor blockade and the risk of osteoporosis: back to the future. Arthritis Res. Ther. 9, 107 (2007).
116. Zwerina J, Redlich K, Polzer K et al.: TNF-induced structural joint damage is mediated by IL-1. Proc. Natl Acad. Sci. USA 104, 11742-11747 (2007).
117. Bresnihan B, Alvaro-Gracia JM, Cobby M et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41, 2196-2204 (1998).
118. Jiang Y, Genant HK, Watt I et al.: A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 43, 1001-1009 (2000).
119. Nuki G, Bresnihan B, Bear MB, McCabe D: Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 2838-2846 (2002).
120. Church LD, McDermott MF: Canakinumab, a fully-human mAb against IL-1β for the potential treatment of inflammatory disorders. Curr. Opin. Mol. Ther. 11, 81-89 (2009).
121. Yogesha SD, Khapli SM, Srivastava RK et al.: IL-3 inhibits TNF-α-induced bone resorption and prevents inflammatory arthritis. J. Immunol. 182, 361-370 (2009).
122. Fonseca JE, Santos MJ, Canhao H, Choy E: Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun. Rev. 2, 2 (2009).
123. Oldfield V, Dhillon S, Plosker GL, Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 69, 609-632 (2009).
124. Baslund B, Tvede N, Danneskiold-Samsoe B et al.: Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum. 52, 2686-2692 (2005).
125. Senolt L, Vencovsky J, Pavelka K, Ospelt C, Gay S: Prospective new biological therapies for rheumatoid arthritis. Autoimmun. Rev. 25, 25 (2009).
126. Fleisch H: Bisphosphonates: mechanisms of action. Endocr. Rev. 19, 80-100 (1998).
127. Breuil V, Euller-Ziegler L: Bisphosphonate therapy in rheumatoid arthritis. Joint Bone Spine 73, 349-354 (2006).
128. Harada H, Nakayama T, Nanaka T, Katsumata T: Effects of bisphosphonates on joint damage and bone loss in rat adjuvant-induced arthritis. Inflamm. Res. 53, 45-52 (2004).
129. Itoh F, Aoyagi S, Kusama H, Kojima M, Kogo H: Effects of clodronate and alendronate on local and systemic changes in bone metabolism in rats with adjuvant arthritis. Inflammation 28, 15-21 (2004).
130. Jarrett SJ, Conaghan PG, Sloan VS et al.: Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum. 54, 1410-1414 (2006).
131. Herrak P, Gortz B, Hayer S et al.: Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum. 50, 2327-2337 (2004).
132. Sims NA, Green JR, Glatt M et al.: Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum. 50, 2338-2346 (2004).
133. Palacios S: Advances in hormone replacement therapy: making the menopause manageable. BMC Womens Health 8, 22 (2008).
134. de Villiers T: The role of menopausal hormone therapy in osteoporosis. Climacteric 10, 71-73 (2007).
135. D'Elia HF, Mattsson LA, Ohlsson C, Nordborg E, Carlsten H: Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1. Arthritis Res. Ther. 5, R202-R209 (2003).
136. Walitt B, Pettinger M, Weinstein A et al.: Effects of postmenopausal hormone therapy on rheumatoid arthritis: the women's health initiative randomized controlled trials. Arthritis Rheum. 59, 302-310 (2008).
137. Stefanick ML: Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am. J. Med. 118, 64-73 (2005).
138. Nielsen RH, Christiansen C, Stolina M, Karsdal MA: Oestrogen exhibits type II collagen protective effects and attenuates collagen-induced arthritis in rats. Clin. Exp. Immunol. 152, 21-27 (2008).
139. Jochems C, Lagerquist M, Hakansson C, Ohlsson C, Carlsten H: Long-term anti-arthritic and anti-osteoporotic effects of raloxifene in established experimental postmenopausal polyarthritis. Clin. Exp. Immunol. 152, 593-597 (2008).
140. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR: The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 16, 348-360 (2001).
141. Anandarajah AP, Schwarz EM: Anti-RANKL therapy for inflammatory bone disorders: mechanisms and potential clinical applications. J. Cell. Biochem. 97, 226-232 (2006).
142. Lewiecki EM, Miller PD, McClung MR et al.: Two-year treatment with denosumab (AMG 162) in a randomized Phase 2 study of postmenopausal women with low BMD. J. Bone Miner. Res. 22, 1832-1841 (2007).
143. McClung MR, Lewiecki EM, Cohen SB et al.: Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 354, 821-831 (2006).
144. Bekker PJ, Holloway DL, Rasmussen AS et al.: A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. 19, 1059-1066 (2004).
145. Cohen SB, Dore RK, Lane NE et al.: Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial. Arthritis Rheum. 58, 1299-1309 (2008).
146. Romas E, Sims NA, Hards D.K. et al.: Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am. J. Pathol. 161, 1419-1427 (2002).
147. Gravallese EM: Bone destruction in arthritis. Ann. Rheum. Dis. 61, II84-II86 (2002).
148. Komuro H, Olee T, Kuhn K et al.: The osteoprotegerin/receptor activator of nuclear factor kB/receptor activator of nuclear factor kB ligand system in cartilage. Arthritis Rheum. 44, 2768-2776 (2001).
149. Salminen-Mankonen HJ, Morko J, Vuorio E: Role of cathepsin K in normal joints and in the development of arthritis. Curr. Drug Targets 8, 315-323 (2007).
150. Hou WS, Li Z, Gordon RE et al.: Cathepsin k is a critical protease in synovial fibroblast-mediated collagen degradation. Am. J. Pathol. 159, 2167-2177 (2001).
151. Stroup GB, Lark MW, Veber DF et al.: Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J. Bone Miner. Res. 16, 1739-1746 (2001).
152. Robichaud J, Oballa R, Prasit P et al.: A novel class of nonpeptidic biaryl inhibitors of human cathepsin K. J. Med. Chem. 46, 3709-3727 (2003).
153. Kumar S, Dare L, JA Vasko-Moser et al.: A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone 40, 122-131 (2007).
154. Robichaud J, Black WC, Therien M et al.: Identification of a nonbasic, nitrile-containing cathepsin K inhibitor (MK-1256) that is efficacious in a monkey model of osteoporosis. J. Med. Chem. 51, 6410-6420 (2008).
155. Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG: Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum. 50, 72-77 (2004).
156. Nielen MM, van Schaardenburg D, Lems WF et al.: Vitamin D deficiency does not increase the risk of rheumatoid arthritis: Comment on the article by Merlino et al. Arthritis Rheum. 54, 3719-3720 (2006).
157. Leventis P, Patel S: Clinical aspects of vitamin D in the management of rheumatoid arthritis. Rheumatology (Oxford) 47, 1617-1621 (2008).
158. Leung BP, Sattar N, Crilly A et al.: A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J. Immunol. 170, 1524-1530 (2003).
159. Kanda H, Yokota K, Kohno C et al.: Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1/Th2 and CD4/CD8 ratios. Mod. Rheumatol. 17, 364-368 (2007).
160. Funk JL, Chen J, Downey KJ, Clark RA: Bone protective effect of simvastatin in experimental arthritis. J. Rheumatol. 35, 1083-1091 (2008).
161. Tourinho TF, Capp E, Brenol JC, Stein A: Physical activity prevents bone loss in premenopausal women with rheumatoid arthritis: a cohort study. Rheumatol. Int. 28, 1001-1007 (2008).
162. Bingham CO 3rd: Emerging therapeutics for rheumatoid arthritis. Bull. NYU Hosp. Jt Dis. 66, 210-215 (2008).
163. Kong YY, Yoshida H, Sarosi I et al.: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323 (1999).
164. Goldring SR, Goldring MB: Eating bone or adding it: the Wnt pathway decides. Nat. Med. 13, 133-134 (2007).
165. Nakamura Y, Nawata M, Wakitani S: Expression profiles and functional analyses of Wnt-related genes in human joint disorders. Am. J. Pathol. 167, 97-105 (2005).
166. Sen M: Wnt signalling in rheumatoid arthritis. Rheumatology (Oxford) 44, 708-713 (2005).
167. Holzhausen M, Spolidorio LC, Ellen RP et al.: Protease-activated receptor-2 activation: a major role in the pathogenesis of Porphyromonas gingivalis infection. Am. J. Pathol. 168, 1189-1199 (2006).
168. Holzhausen M, Spolidorio LC, Vergnolle N: Proteinase-activated receptor-2 (PAR2) agonist causes periodontitis in rats. J. Dent. Res. 84, 154-159 (2005).
169. Abraham LA, Jenkins AL, Stone SR, Mackie EJ: Expression of the thrombin receptor in developing bone and associated tissues. J. Bone Miner. Res. 13, 818-827 (1998).
170. Smith R, Ransjo M, Tatarczuch L et al.: Activation of protease-activated receptor-2 leads to inhibition of osteoclast differentiation. J. Bone Miner. Res. 19, 507-516 (2004).
171. Ferrell WR, Lockhart JC, Kelso EB et al.: Essential role for proteinase-activated receptor-2 in arthritis. J. Clin. Invest. 111, 35-41 (2003).
172. Chen LF, Greene WC: Shaping the nuclear action of NF-kB. Nat. Rev. Mol. Cell Biol. 5, 392-401 (2004).
173. Trepel J, Birrer MJ: Link A between histone deacetylase inhibitors and NF-kB signaling. Cell Cycle 2, 452-453 (2003).
174. Richon VM, O'Brien JP: Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. Clin. Cancer Res. 8, 662-664 (2002).
175. Chung YL, Lee MY, Wang AJ, Yao LF: A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol. Ther. 8, 707-717 (2003).
176. Nakamura T, Kukita T, Shobuike T et al.: Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-β production. J. Immunol. 175, 5809-5816 (2005).
177. Butler KV, Kozikowski AP: Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr. Pharm. Des. 14, 505-528 (2008).
178. Itoh Y, Suzuki T, Miyata N: Isoform-selective histone deacetylase inhibitors. Curr. Pharm. Des. 14, 529-544 (2008).
179. Monneret C: Histone deacetylase inhibitors. Eur. J. Med. Chem. 40, 1-13 (2005).
180. Lin HS, Hu CY, Chan HY et al.: Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br. J. Pharmacol. 150, 862-872 (2007).
181. Wong PK, Quinn JM, Sims NA, van Nieuwenhuijze A, Campbell IK, Wicks IP: Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum. 54, 158-168 (2006).
182. Mihara M, Moriya Y, Kishimoto T, Ohsugi Y: Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br. J. Rheumatol. 34, 321-325 (1995).
183. Yago T, Nanke Y, Kawamoto M et al.: IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res. Ther. 9, R96 (2007).
184. Jimi E, Nakamura I, Duong LT et al.: Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp. Cell Res. 247, 84-93 (1999).
185. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S: Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25, 255-259 (1999).
186. Hashizume M, Hayakawa N, Mihara M: IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17. Rheumatology (Oxford) 47, 1635-1640 (2008).
187. Chen L, Wei XQ, Evans B, Jiang W, Aeschlimann D: IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kB (RANK) expression in myeloid precursor cells. Eur. J. Immunol. 38, 2845-2854 (2008).
188. Komine M, Kukita A, Kukita T, Ogata Y, Hotokebuchi T, Kohashi O: Tumor necrosis factor-α cooperates with receptor activator of nuclear factor kB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. Bone 28, 474-483 (2001).
189. Quinn JM, Horwood NJ, Elliott J, Gillespie MT, Martin TJ: Fibroblastic stromal cells express receptor activator of NF-kB ligand and support osteoclast differentiation. J. Bone Miner. Res. 15, 1459-1466 (2000).
190. Kotake S, Sato K, Kim KJ et al.: Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J. Bone Miner. Res. 11, 88-95 (1996).
191. Kotake S, Udagawa N, Takahashi N et al.: IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103, 1345-1352 (1999).
192. Welfare AIoHa: A Picture of Rheumatoid Arthritis in Australia. Ageing HA (Ed.), (2009). www.aihw.gov.au/publications/index.cfm/title/10524
193. Chondrex Inc.: Arthrogen-CIA Arthritogenic Monoclonal Antibodies. 2007, 2009. www.chondrex.com/uploads/2008_Catalog_2_Web.pdf